GE HealthCare has launched a theranostics research collaboration with Mayo Clinic to study radioligand therapy (RLT) for patients with advanced prostate cancer.
The Molecular Imaging Biomarker-Based End of Therapy Trial (MI-BET) will evaluate whether imaging and biomarker data can support adaptive RLT treatment based on the patient's disease response, rather than following a preset number of treatment cycles, according to GE HealthCare.
The study will use GE HealthCare's StarGuide SPECT/CT system alongside MIM Software's MIM LesionID Pro to track tumor response throughout therapy, integrating imaging data with clinical outcomes and blood-based biomarkers.
Research will be based at Mayo Clinic's campus in Rochester, MN, which is the first U.S. site to investigate the StarGuide GX SPECT/CT technology, GEHC noted. StarGuide GX is CE marked but has not been approved or cleared by the U.S. Food and Drug Administration (FDA).
The collaboration extends a 2023 strategic radiology research alliance between the two organizations, the company said.
